Literature DB >> 12913757

Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model.

Chao-Nan Qian1, Masayuki Takahashi, Richard J Kahnoski, Bin Tean Teh.   

Abstract

PURPOSE: We characterized the effects of sildenafil citrate on the growth and metastasis of human prostate cancer cells in nude mice.
MATERIALS AND METHODS: The androgen independent human prostate cancer cell line PC-3 was inoculated into the prostate of nude mice to produce orthotopic primary prostate cancers and metastases. Sildenafil citrate gavage was started on day 31 after tumor cell inoculation and given every other day 15 times (30 days). The 7 mice in the low dose group received 25 mg/kg body weight sildenafil citrate per gavage, while the 7 in the high dose group received 50 mg/kg body weight sildenafil citrate and the 9 in the control group received water. Autopsy was performed on day 75 to evaluate primary tumor growth and metastasis. Plasma cyclic guanosine monophosphate concentrations were measured after the single dose of 50 mg/kg sildenafil citrate in the mice.
RESULTS: Plasma cyclic guanosine monophosphate concentration increased 4-fold 1 hour after sildenafil citrate administration. The plasma concentration decreased rapidly and returned to normal after 8 hours. There was no significant difference in tumor weight between any of the 3 groups. The number of metastatic lymph nodes correlated significantly with primary tumor weight (p = 0.03) with a correlation coefficient of 0.454 but there was no significant correlation between the number of involved lymph nodes and sildenafil administration. Distant metastases were not significantly promoted by sildenafil administration.
CONCLUSIONS: Incontinuous oral administration of sildenafil citrate did not promote primary tumor growth and metastasis in an orthotopic prostate cancer model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913757     DOI: 10.1097/01.ju.0000080321.99119.df

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Semiquantitative imaging measurement of baseline and vasomodulated normal prostatic blood flow using sildenafil.

Authors:  J R Haaga; A Exner; B Fei; A Seftel
Journal:  Int J Impot Res       Date:  2006-05-25       Impact factor: 2.896

2.  Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.

Authors:  Qing He; Bang-Hua Liao; Kai-Wen Xiao; Liang Zhou; Shi-Jian Feng; Hong Li; Kun-Jie Wang
Journal:  Int Urol Nephrol       Date:  2018-09-19       Impact factor: 2.370

3.  Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer.

Authors:  Thomas K Hamilton; Nianping Hu; Klodiana Kolomitro; Erin N Bell; Donald H Maurice; Charles H Graham; D Robert Siemens
Journal:  World J Urol       Date:  2012-03-02       Impact factor: 4.226

4.  Phosphodiesterase 5 inhibitor sildenafil potentiates the antitumor activity of cisplatin by ROS-mediated apoptosis: a role of deregulated glucose metabolism.

Authors:  Shiv Govind Rawat; Rajan Kumar Tiwari; Pradip Kumar Jaiswara; Vishal Kumar Gupta; Pratishtha Sonker; Naveen Kumar Vishvakarma; Santosh Kumar; Chandramani Pathak; Vibhav Gautam; Ajay Kumar
Journal:  Apoptosis       Date:  2022-06-20       Impact factor: 5.561

5.  The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.

Authors:  Juzar Jamnagerwalla; Lauren E Howard; Adriana C Vidal; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Stephen J Freedland
Journal:  J Urol       Date:  2016-04-05       Impact factor: 7.450

6.  Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency.

Authors:  M Khairallah; R J Khairallah; M E Young; B G Allen; M A Gillis; G Danialou; C F Deschepper; B J Petrof; C Des Rosiers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-12       Impact factor: 11.205

Review 7.  Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.

Authors:  Su Jin Kim; Ju Ho Kim; Hyun-Kyung Chang; Khae Hawn Kim
Journal:  J Exerc Rehabil       Date:  2016-06-30

Review 8.  Phosphodiesterase type 5 and cancers: progress and challenges.

Authors:  Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano
Journal:  Oncotarget       Date:  2017-10-12

9.  Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.

Authors:  Pan Pantziarka; Vidula Sukhatme; Sergio Crispino; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2018-04-11

10.  Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range.

Authors:  William Hankey; Benjamin Sunkel; Fuwen Yuan; Haiyan He; Jennifer M Thomas-Ahner; Zhong Chen; Steven K Clinton; Jiaoti Huang; Qianben Wang
Journal:  Transl Oncol       Date:  2020-05-23       Impact factor: 4.803

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.